Conditions: Severe Thrombocytopenia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This is an open-label study in which oprelvekin will be administered for the prevention of severe low blood platelet cell counts (cells in your blood that keep bleeding and clotting stable) in adults with cancer who are taking chemotherapy (anti-cancer drug) that has a side effect of blocking your bone marrow from making platelet cells. The purpose of this study is to learn more about the effects of the recommended dose of oprelvekin on the heart's electrical cycle.

Detailed description:

Arms:
arm 1: Open label treatment with oprelvekin

Interventions: intervention 1: oprelvekin
Intervention descriptions: intervention 1: injection, 50 mg/kg, once daily

Protocol document: